We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Levrett | LSE:LVRT | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLVRT
RNS Number : 3197T
Levrett PLC
29 March 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE UNITED STATES OF AMERICA OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.
For Immediate Release 29 March 2016
Levrett Plc
("Levrett" or "the Company")
Interim Results
for the period ended 31 December 2015
Levrett, a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces its interim results for the period ended 31 December 2015.
Enquiries:
Levrett Plc Pascal Hughes, CEO +44 (0) 20 7183 4342 EGR Broking Limited Leo Godsall / Jonathan Hall +44 (0)203 697 9496 Whitman Howard Limited Niall Baird / Nick Lovering +44 (0) 20 7659 1234 Gable Communications Limited +44 (0) 20 7193 7463 John Bick +44 (0) 7872 061007 e: levrett@gablecommunications.com
LEVRETT PLC
CHAIRMAN'S STATEMENT
FOR THE PERIOD ENDED 31 DECEMBER 2015
Introduction
These are the results for Levrett Plc for the interim period ended 31 December 2015.
The company was incorporated on 10 June 2015 and was admitted to the Official List of the UK Listing Authority on 17 December 2015.
Financial review
In the period to 31 December 2015, the Company recorded a loss of GBP197,929 (a loss per share of 0.37 pence). This includes certain non-recurring fees from the admission of shares to trading on the Standard List of the Main Market of the London Stock Exchange. The Company continues to be run with a measured and strategic approach to focus expenditure on identifying acquisition targets and performing necessary due diligence. The board does not recommend the payment of a dividend at this time.
Outlook
The recent announcements with regards to Immuno-Oncology advances highlights one example of how the Biotechnology sector in the UK continues to evolve and develop. There are a number of significant opportunities that would make suitable investment targets for Levrett, which was formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector.
The Company has made considerable progress towards identifying such targets focussed on four specific strategic sectors, being; Oncology, Diabetes, Obesity and Mental Health. The Board has reviewed a number of specific targets to date, within the UK, Europe and the United States. Whilst some of these have not met the investment criteria for the Company, the Board continues to review the other opportunities with a view to completing a suitable acquisition.
F J Lidgey
Chairman
29 March 2016
LEVRETT PLC
INTERIM STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 DECEMBER 2015
Unaudited period ended 31 December 2015 GBP Revenue - Administrative expenses (197,929) LOSS BEFORE TAX (197,929) Tax - LOSS FOR THE PERIOD (197,929) ------------- Other comprehensive - income/(expense) TOTAL COMPREHENSIVE EXPENSE FOR THE PERIOD (197,929) =============
Loss before tax and total comprehensive expense for the period are all attributable to the equity shareholders of the company.
Loss per share Basic and diluted (0.37)p ========
LEVRETT PLC
INTERIM STATEMENT OF FINANCIAL POSITION
FOR THE PERIOD ENDED 31 DECEMBER 2015
Unaudited 31 December 2015 Notes GBP ASSETS Current assets Trade and other receivables 39,691 Cash and cash equivalents 684,901 ------------ 724,592 TOTAL ASSETS 724,592 ============ EQUITY AND LIABILITIES Equity Share capital 3 95,750 Share premium account 757,010 Retained earnings (197,929) Total equity attributable to equity holders of the parent 654,831 ------------ Current liabilities Trade and other payables 69,761 TOTAL LIABILITIES 69,761 ------------ TOTAL EQUITY AND LIABILITIES 724,592 ============
LEVRETT PLC
INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DECEMBER 2015
Share Share Premium Retained capital account earnings Total GBP GBP GBP GBP On Incorporation - - - - Total comprehensive expense for the period - - (197,929) (197,929) Shares issued in the period 95,750 757,010 - 852,760 Unaudited at 31 December 2015 95,750 757,010 (197,929) 654,831 ======== ======== ============ ============
All equity is attributable to equity shareholders of the company.
Share premium
Represents amounts subscribed for share capital in excess of its nominal value, net of directly attributable issue costs.
LEVRETT PLC
INTERIM STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED 31 DECEMBER 2015
Unaudited period ended 31 December 2015 GBP Operating activities Loss before tax (197,929) Changes in working capital: Increase in trade and other receivables (39,691) Increase in trade and other payables 69,761 Net cash used in operating activities (167,859) Financing activities Share issue (net of costs) 852,760 Net cash generated from financing activities 852,760 Taxation - Net increase in cash and cash equivalents 684,901 Cash and cash equivalents - at the start of the period ------------- Cash and cash equivalents at the end of the period 684,901 =============
LEVRETT PLC
NOTES TO THE INTERIM FINANCIAL INFORMATION
FOR THE PERIOD ENDED 31 DECEMBER 2015
1 General information
Levrett Plc is a publicly listed company incorporated and domiciled in England. The address of its registered office is Suite 31. 2(nd) Floor, 107 Cheapside, London. EC2V 6DN.
The Company is listed on the Official List.
This interim financial information was approved for issue on 29 March 2016.
2 Accounting policies 2.1 Basis of preparation
The interim financial information comprises the Statements of Financial Position at 31 December 2015, the Statements of Comprehensive Income, Changes in Equity and Cash Flows for the period ended 31 December 2015 and the related notes of Levrett Plc, (hereinafter referred to as 'the interim financial information).
The interim financial information has been prepared in accordance with IAS 34, 'Interim Financial Reporting' as adopted by the European Union. In preparing this information, management have used the accounting policies set by the Company.
This interim financial information does not constitute a set of statutory accounts under the requirements of the Companies Act 2006 and is neither audited nor reviewed.
This document (the Interim Statement 2015) will be published on the company's website and will be publicly available from the London Stock Exchange regulatory publications. The maintenance and integrity of the Levrett Plc website is the responsibility of the directors. Legislation in the UK governing the preparation and dissemination of accounts may differ from legislation in other jurisdictions.
2.2 Going concern
These financial statements have been prepared on the going concern basis based on the current cash flow projections for the following twelve months.
LEVRETT PLC
NOTES TO THE INTERIM FINANCIAL INFORMATION
FOR THE PERIOD ENDED 31 DECEMBER 2015
3 Share capital Unaudited period ended 31 December 2015 GBP Issued and fully paid 95,750,000 Ordinary shares issued of GBP0.001 each 95,750 ------------- 95,750 =============
(MORE TO FOLLOW) Dow Jones Newswires
March 29, 2016 02:01 ET (06:01 GMT)
On Admission to the Official List, 45,750,000 of the above issued share capital was placed at a price of GBP0.02 per share with the premium (net of the issue costs) being shown in the share premium account.
On 7 December 2015, the company issued 50,000,000 founder warrants to the founder shareholders which entitles each warrant holder to subscribe for one ordinary share at 4 pence per share, exercisable any time.
On the same date, the company issued 957,500 warrants to EGR Broking Limited which entitles each warrant holder to subscribe for one ordinary share at 2 pence per share, exercisable any time.
Dividends paid 4 and proposed Equity dividends on ordinary shares: No interim dividend was paid or is proposed for the period ended 31 December 2015. Loss per 5 share
The calculations of loss per share are based on the following results and number of shares:
Unaudited period ended 31 December 2015 GBP Loss for the financial period (197,929) ============ Weighted average number of shares for diluted loss per share 53,124,390 ============ At 31 December 2015, the number of ordinary shares in issue was 95,750,000.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR EAFDPAEDKEFF
(END) Dow Jones Newswires
March 29, 2016 02:01 ET (06:01 GMT)
1 Year Levrett Chart |
1 Month Levrett Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions